Suryadevara, Naveenchandra http://orcid.org/0000-0003-2571-1290
Otrelo-Cardoso, Ana Rita
Kose, Nurgun
Hu, Yao-Xiong
Binshtein, Elad
Wolters, Rachael M. http://orcid.org/0000-0003-2896-7515
Greninger, Alexander L. http://orcid.org/0000-0002-7443-0527
Handal, Laura S. http://orcid.org/0000-0001-8658-4411
Carnahan, Robert H. http://orcid.org/0000-0001-5230-1532
Moscona, Anne http://orcid.org/0000-0002-1796-8320
Jardetzky, Theodore S. http://orcid.org/0000-0002-3664-0072
Crowe, James E. Jr. http://orcid.org/0000-0002-0049-1079
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI13752, R01 AI114736, R01 AI13752)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (U24 GM129541)
Article History
Received: 2 August 2023
Accepted: 2 May 2024
First Online: 10 June 2024
Competing interests
: J.E.C. has served as a consultant for Luna Labs USA, Merck Sharp & Dohme Corporation, Emergent Biosolutions, and BTG International Inc., is a member of the Scientific Advisory Board of Meissa Vaccines, a former member of the Scientific Advisory Board of Gigagen (Grifols) and is founder of IDBiologics. The laboratory of J.E.C. received unrelated sponsored research agreements from AstraZeneca, Takeda Vaccines, and IDBiologics during the conduct of the study. T.S.J. has served as a consultant for Pfizer. A.L.G reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen and Hologic, and research support from Gilead, outside of the described work. A.M. reports potential future financial interests in Thylacine Biotherapeutics Inc. unrelated to the present study. All other authors declare no competing interests. Vanderbilt University has applied for a patent for some of the antibodies in this paper (2024 International Patent Application No. PCT/US2024/028239 based on US Serial No. 63/504,549).